Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Santen Pharmaceutical Co ( (JP:4536) ) has shared an announcement.
Santen Pharmaceutical Co. reported a decline in its financial performance for the three months ended June 30, 2025, with significant decreases in revenue, core operating profit, and net profit compared to the same period in the previous year. Despite these declines, the company maintains its dividend forecasts for the fiscal year ending March 31, 2026, and has resolved to undertake a share repurchase, indicating a strategic move to enhance shareholder value.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen2200.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd is a company listed on the Tokyo Stock Exchange’s Prime Market, primarily engaged in the pharmaceutical industry. The company focuses on developing and providing ophthalmic products and services, catering to a global market with a strong emphasis on eye health.
Average Trading Volume: 1,267,079
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen563.2B
Find detailed analytics on 4536 stock on TipRanks’ Stock Analysis page.